Find A Research Study
Study Title: Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
Category: Cancer, General
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Thomas Malpass
Study Coordinator: Kathy Rabena
Phone: (206) 223-6892 Ext.36892
Email: hemckr@vmmc.org
What is the Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212) study?
Who can participate?
~Histological daignosis fo primary peritoneal carcinoma or epithelial ovarain carcinoma, Stage II or IV.
~Has completed treatmetn with the past 12 weeks with at least 5 cylces and no more than 8 cycles of platinum and paclitaxel or codetaxel-based combination chemotherapy and have no symptoms suggestive or persistant cancer.
N~Normal CT scan of the abdomen/pelvis and normal CA-125 following treatment
Ineligibility:
~Patients with current diagnosis of epithelial ovarian tumor of low malignant potential are not eligible.
~patietns who have recieved prior radiotherapy to any portion of the abdominal cavity or pelvis.
~Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer.
~No other malignancies within the last 5 years
What do I have to do as a study participant?
Study Summary:
Detailed Study Description:
Study Design: Interventional, Observational
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Ovarian or Primary Peritoneal Cancer
Intervention Type: Drug
Intervention Name: CT-2103
Gender: Female
Age group: Interventional
Sponsor: Gynecological Oncology Group (GOG)
Other studies in this category include:
Studies currently accepting study participants:
- A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC),
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- AMC047: AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
- Brain Metastases in NSCLC (RTOG 0320)
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- PGT307 - Paclitaxel Poliglumex plus Carboplatin for the treatment of non-small cell lung cancer in women.
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Sorafenib vs Placebo for Hepatocellular Carcinoma
- Stage IV Urothelial Cancer
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer
Studies currently not accepting study participants:
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer